Key features and details
- FITC Mouse monoclonal [DR-4-02] to DR4
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG1
Product nameFITC Anti-DR4 antibody [DR-4-02]
See all DR4 primary antibodies
DescriptionFITC Mouse monoclonal [DR-4-02] to DR4
ConjugationFITC. Ex: 493nm, Em: 528nm
SpecificityThe antibody recognizes TRAIL R1 (DR4), a human death receptor 4 (468 amino acids) expressed in most human tissues (spleen, peripheral blood leucocytes, thymus) and in a variety of tumour derived cell lines.
Species reactivityReacts with: Human
Fusion protein (Human) containing the extracellular part of DR4 and the constant part of the heavy chain of human IgG1.
General notesDo not use after expiration date stamped on vial label. Short term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.
Soluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells.
The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferpH: 7.4
Preservative: 0.097% Sodium azide
Constituent: 0.2% BSA
0.2% high grade protease free BSA
Concentration information loading...
Purification notesThe antibody was >95% pure prior to conjugation as determined from SDS-PAGE (by protein A affinity chromatography).
Primary antibody notesSoluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells.
FunctionReceptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B.
Tissue specificityWidely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K562 erythroleukemia cells, MCF7 breast carcinoma cells and activated T-cells.
Sequence similaritiesContains 1 death domain.
Contains 3 TNFR-Cys repeats.
- Information by UniProt
- Apo2 antibody
- CD261 antibody
- Cytotoxic TRAIL receptor antibody
ab59047 has been referenced in 4 publications.
- Strekalova E et al. Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction. Methods Mol Biol 1866:61-73 (2019). PubMed: 30725408
- Piggott L et al. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. Clin Cancer Res 24:2452-2463 (2018). PubMed: 29363524
- Nesterenko I et al. Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas. PLoS One 7:e49219 (2012). Flow Cyt ; Human . PubMed: 23145127
- Fan S et al. Scatter factor protects tumor cells against apoptosis caused by TRAIL. Anticancer Drugs 21:10-24 (2010). IP . PubMed: 19823077